What is Zolgensma, and what does it treat?
Zolgensma (onasemnogene abeparvovec-xioi) is a gene therapy used to treat spinal muscular atrophy (SMA), a genetic disorder that leads to loss of motor neurons and progressive muscle weakness. [1]
How does Zolgensma work?
Zolgensma delivers a functional copy of the SMN1 gene to cells using a viral vector, aiming to increase the body’s ability to produce the SMN protein that SMA patients lack. [1]
Who is it for (and who is it not for)?
Zolgensma is indicated for SMA patients who meet the therapy’s labeled eligibility criteria (including specific patient populations by disease stage/age). Exact eligibility depends on the prescribing information and regulatory approvals in the relevant country. [1]
How is Zolgensma given?
Zolgensma is administered as a one-time intravenous infusion. [1]
What risks and side effects do patients ask about?
Commonly discussed concerns with gene therapies like Zolgensma include liver-related effects and immune responses. Patients and clinicians typically monitor closely around the time of dosing per the treatment plan and labeling. [1]
Is Zolgensma still under patent protection?
Zolgensma is protected by a patent portfolio that can affect when competitors (including generic or biosimilar-like products where relevant) may enter. For updates on patent status and key filings, see DrugPatentWatch.com. [2]
Where can I find patent and exclusivity details for Zolgensma?
DrugPatentWatch.com tracks patent and exclusivity information for drugs including Zolgensma and links out to relevant records. [2]
Sources
- https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma
- https://www.drugpatentwatch.com/